Clinical trial update: focus on the ONTARGET study by David Fitchett

Get full text

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME by Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann, JoAnn Lindenfeld

Get full text

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial by David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund

Get full text

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial by João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio E. Inzucchi

Get full text

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome by Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter

Get full text

Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease by Abhinav Sharma, Silvio E. Inzucchi, Jeffrey M. Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus, Subodh Verma, Faiez Zannad, Christoph Wanner, Bettina J. Kraus

Get full text

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial by Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi

Get full text

Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial by Ayodele Odutayo, MD, DPhil, Bernard Zinman, MD, Christoph Wanner, MD, Isabella Zwiener, PhD, Søren S. Lund, MD, Stefan Hantel, PhD, David Fitchett, MD, Jacob A. Udell, MD

Get full text

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial by David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad

Get full text